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Abstract
Background: Covalent modification of nuclear receptors by the Small Ubiquitin-like Modifier (SUMO) is dynamically
regulated by competing conjugation/deconjugation steps that modulate their overall transcriptional activity. SUMO
conjugation of progesterone receptors (PRs) at the N-terminal lysine (K) 388 residue of PR-B is hormone-dependent
and suppresses PR-dependent transcription. Mutation of the SUMOylation motif promotes transcriptional synergy.
Results: The present studies address mechanisms underlying this transcriptional synergy by using SUMOylation
deficient PR mutants and PR specifically deSUMOylated by Sentrin-specific proteases (SENPs). We show that
deSUMOylation of a small pool of receptors by catalytically competent SENPs globally modulates the cooperativity-
driven transcriptional synergy between PR observed on exogenous promoters containing at least two
progesterone-response elements (PRE2). This occurs in part by raising PR sensitivity to ligands. The C-terminal
ligand binding domain of PR is required for the transcriptional stimulatory effects of N-terminal deSUMOylation,
but neither a functional PR dimerization interface, nor a DNA binding domain exhibiting PR specificity, are required.
Conclusion: We conclude that direct and reversible SUMOylation of a minor PR protein subpopulation tightly
controls the overall transcriptional activity of the receptors at complex synthetic promoters. Transcriptional
synergism controlled by SENP-dependent PR deSUMOylation is dissociable from MAPK-catalyzed receptor
phosphorylation, from SRC-1 coactivation and from recruitment of histone deacetylases to promoters. This will
provide more information for targeting PR as a part of hormonal therapy of breast cancer. Taken together, these
data demonstrate that the SUMOylation/deSUMOylation pathway is an interesting target for therapeutic treatment
of breast cancer.
Background
Progesterone plays a key role in the development, differen-
tiation and maintenance of normal and malignant female
tissues. Its effects are mediated by progesterone receptors
(PRs), members of the steroid hormone receptor super-
family of ligand-dependent transcription factors. PRs exist
as two major, functionally different [1] isoforms–PR-A
(~94 kDa) and PR-B (~110 kDa). They are multidomain
proteins consisting of a central DNA-binding domain
(DBD); large N-termini with a proximal activation func-
tion (AF-1) common to both isoforms; a distal AF-3 in the
B-upstream segment (BUS) restricted to PR-B; and at their
C-termini, a nuclear localization signal in a hinge region
upstream of an AF-2-containing ligand binding domain
(LBD) [1-5]. PRs are transactivators that can be tethered
to DNA through other transcription factors [6-10] but
more commonly are bound directly to DNA at palindro-
mic progesterone-response elements (PREs) [11]. The two
isoforms bind DNA with equivalent affinity [12] so this
cannot explain their functional differences. Rather, dissim-
ilar coregulator recruitment has been invoked for their
differences [13]. These coactivators or corepressors facili-
tate receptor/DNA occupancy, chromatin remodeling and
recruitment of general transcription factors associated
with the RNA polymerase II holocomplex [14]. Function
of the receptors and their coregulators are in turn
controlled by posttranslational modifications including
phosphorylation, acetylation, ubiquitination and SUMOy-
lation [15] that influence hormone sensitivity and promo-
ter selectivity, among others [16]. Ubiquitination for
example, promotes ligand-dependent PR protein downre-
gulation via proteasomal degradation, which paradoxically
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modifications are reversible, enzymes that dephosphory-
late, deacetylate, deubiquitinate and deSUMOylate PRs
also alter activity [16,18-20], so that permutations of these
modifications undoubtedly play a large role in the complex
signaling patterns ascribed to the receptors [1].
Transcriptional synergy and PR SUMOylation
Additional complexity arises from the structure of DNA
to which PRs bind. Cooperativity among receptors bound
at compound promoters consisting of two or more PREs
results in synergism defined as a “more-than-additive”
transcriptional effect [21]. Iniguez-Lluhi and Pearce [21]
f i r s ti d e n t i f i e das h o r ts y n e r gy control (SC) motif in glu-
cocorticoid receptors (GR) that disrupted synergy on
promoters with multiple response elements. Its mutation
induced strong synergistic effects but only at compound
response elements. The SC motif turned out to be a
SUMOylation site at which conjugation of SUMO-1, a 97
amino acid (aa) Small Ubiquitin-like Modifier, disrupted
synergy [22-24]. Similar sites in both GR and PR [15]
contain a lysine (Lys, K) residue embedded in the consen-
sus sequence ΨKxE (where Ψ is a large hydrophobic
amino acid, and x is any amino acid) located in the
N-terminal AF-1 domains of the receptors. For human
PR-B this sequence is centered at K388, and at a homolo-
gous site of PR-A. Monomeric SUMO-1 covalently binds
this site through a series of dynamic and reversible enzy-
matic reactions involving an E1 SUMO activating
enzyme, an E2 conjugating enzyme (Ubc9) and E3 ligases
(PIASs; Protein Inhibitors of Activated STAT (Signal
Transducer and activator of transcription)). DeSUMOyla-
tion is catalyzed by one of six human Sentrin-specific
proteases (SENPs) that target SUMO. Largely due to
their roles in modifying the activity of steroid receptors,
both Ubc9 and PIAS have at times been classified as tran-
scriptional coregulators [25-27]. Mouse knockouts of
Ubc9 or SENP1 are embryonic lethal, demonstrating that
the balance of SUMOylation and deSUMOylation is
essential for development [28,29]. Most, but not all ster-
oid receptors–the exception appearing to be estrogen
receptors (ER)–are targets of SUMOylation. This is con-
sistent with the fact that phylogenetic and sequence
alignments of GR, mineralocorticoid receptors (MR),
androgen receptors (AR) and PR links them to a steroid
receptor subfamily characterized by much larger N-ter-
mini (ranging from 420 to 602 aa) than the N-termini of
ERa or ERb (184 and 148 aa, respectively). As a result in
vitro translated AR and GR, but not ERa or ERb,a r e
SUMOylated [30].
S U M Oc o n j u g a t i o no fP R - Ba tK 3 8 8( o rt h eP R - A
equivalent) is hormone dependent and occurs via PIAS1
[31] or PIAS3 [32]. This suppresses PR -dependent tran-
scription of promoters containing multiple PREs but not
a single PRE [6,18,33-35]. Additionally, overexpression of
PIAS3 can induce PR-B SUMOylation at K7 and K531
[32] but the physiological relevance of this is unclear.
S U M Oi sd e c o n j u g a t e df r o mt he receptors by SENPs,
which, like deSUMOylation by mutation of K388, drama-
tically enhances PR transcriptional activity [18]. The
relationship between the transcriptional efficacy of deSU-
MOylation and the role of ligand-dependent PR downre-
gulation are contradictory. Zhang and coworker [36]
showed that mutation of PR-B at K388 retards progester-
one-induced degradation through the ubiquitin-protea-
some pathway. In contrast, we and others [6,18] have
shown that PR K388R mutants undergo accelerated
ligand-dependent downregulation thereby explaining
their heightened transcriptional activity.
In the present study we analyze the functional effects of
SENP-induced PR deSUMOylation in detail. Our results
indicate that on a compound promoter, SENP1 enhances
transcription in a dose-dependent manner, but this
requires full-length PR. However enhanced transcription is
independent of PR DNA binding specificity or the PR
S294 phosphorylation site. By deSUMOylating PR, SENP
increases PR sensitivity to hormone. The histone deacety-
lase inhibitor Trichostatin A (TSA) has a marked biphasic
effect. At high concentrations, which promote global his-
tone hyperacetylation and modify many proteins [37],
TSA strongly suppresses transcription and this is reversed
by the coactivator SRC-1. However, low TSA concentra-
tions upregulate PR-dependent transcription. This effect
of TSA is uncoupled from inhibition by SUMOylation
indicating that HDAC activity is not involved in transcrip-
tional synergy controlled by SENP1.
Results
SENP and PR deSUMOylation
SUMOylation and the promoter context of PR
transcriptional synergy
Figure 1A is a schematic of PR-B and PR-A showing
location of the single ψKxE SUMO-conjugation motif
centered at K388 of PR-B (and a homologous K224 of
PR-A). Also shown are 3 hormone dependent serine
(S102, S294 and S345) and multiple other (thin lines)
N-terminal phosphorylation sites, and a hinge domain
KxKK (aa 638-641) acetylation site.
We previously showed [6] that SUMOylation at K388 (or
K224) is hormone-dependent and suppresses PR-B and
PR-A-regulated transcription of an exogenous promoter
containing two (PRE2) or more palindromic PREs but not
a single PRE. To assess the generality of this, we used the
MMTV-LTR, which contains 1 palindromic PRE and 3
PRE half-sites. In contrast to GRs that prefer the palin-
drome, the half-sites are preferentially used by PRs [38],
possibly as monomers [39]. To examine the role of PR
SUMOylation on transcriptional synergy involving PRE
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Figure 1 Modulation of PR transcriptional activity by SUMO-1 depends on the promoter context. A) schematic of PR-A and PR-B showing
the location of hormone dependent phosphorylation sites; the Lys-388 SUMO conjugation site within an IKEE motif; and an acetylation
consensus KxKK site (amino acids 638-641). BUS, B-upstream segment; DBD, DNA binding domain; LBD, ligand binding domain. B) HeLa cells
were transfected with 2 μg of PRE2-Luc reporter, or C) MMTV-Luc, together with 5-1000 ng of wild-type PR-B or mutant PR-B K388R expression
vectors and Renilla-Luc as an internal control. The cells were treated 24 hrs with 10 nM R5020, then harvested and lysed. The extracts were
assayed for luciferase activities. Luciferase activity is expressed in relative light units (RLU). Data represent triplicates (± SD). Statistical significance
was computed by unpaired student’s t test. *p < 0.05.
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DNA encoding wild-type PR-B or the SUMOylation-defi-
cient K388R PR-B mutant [33], together with the PRE2-
Luc (Figure 1B) or MMTV-Luc (Figure 1C) reporters, in
the presence of the progestin R5020. PR-B were tested
since they are more potent transactivators of the MMTV-
LTR than PR-A [40]. On PRE2-Luc, wild-type PR-B were
transcriptionally active, and mutation of their K388
SUMOylation motif synergistically raised transcription
further as receptor concentrations were increased between
5 and 100 ng DNA. High PR concentrations (500 and 1000
ng DNA) led to a decrement in transcription likely due to
transcription factor “squelching” [33]. Wild-type PR-B
dependent transcription on MMTV-LTR showed a similar
dose-dependent increase. However, absolutely no tran-
scriptional synergy was observed with the K388R PR-B
mutant suggesting that SUMOylation does not control
synergy on PRE half-sites. Most of the studies below use
PRE2-Luc
DeSUMOylation by SENP
The K388R PR mutant is an artificial construct while
proteins are naturally deSUMOylated by SENPs in vivo
[18]. To examine effects of in vivo PR deSUMOylation,
wild-type PR-B (1 μgD N A )a n dG F P - S U M O 1( 0 . 1μg
DNA) were cotransfected into HeLa cells together with
SENP1 or SENP2 expression vectors (0.1 μgD N A ) ,a n d
unliganded or liganded PR-B SUMOylation states were
assessed by immunoblotting (Figure 2A). PR-B are not
SUMOylated by ligand in the absence of SUMO-1 (lane
2 ) ,o rb yS U M O - 1i nt h ea b s e n c eo fl i g a n d( l a n e3 ) ,b u t
approximately 5% of the receptors are SUMOylated
when both are present (lane 4). However, in cells co-
expressing SENP1 (lane 6) or SENP2 (lane 8) SUMO1-
PR conjugates are essentially absent. A R630L, K631M
SENP1 mutant (SENP1m), whose catalytic function is
disabled [20], was unable to deSUMOylate PR (Addi-
tional file 1: Figure S1A).
We next tested effects of increasing concentrations of
DNA (20-1000 ng) encoding SENP1, SENP1m and SENP2
on PRE2-Luc transcription by R5020-liganded, wild-type
PR-B transiently expressed in HeLa cells (Figure 2B) or
stably expressed in T47D breast cancer cells (Additional
file 1: Figure S1B). Analogous to the K388R SUMOyla-
tion-deficient PR-B mutant, deSUMOylation by SENP1
and SENP2 strongly enhanced the transcriptional activity
of wild-type liganded PR-B in both cell types in a dose-
dependent manner. The SENP1m control was ineffective
(Figure 2B). It is of interest that these extensive transcrip-
tional effects of SUMOylation/deSUMOylation are
regulated by a minor subpopulation of PR molecules
(Figure 2A). Indeed, the PR SUMOylation state and its
control of transcription applies even to weak progestin
agonists as shown by the fact that deSUMOylation by
SENPs intensifies transcription by the mixed agonist/
antagonist RU486 [41], but has no effect on transcrip-
tion by the pure antagonist ZK98299 (Additional file 1:
Figure S1C
The above results indicate that the activity of agonist-
occupied PRs can be regulated dynamically and reversibly
by SUMOylation/deSUMOylation of a small receptor sub-
population. To demonstrate whether this is a direct effect
on PRs, or an indirect effect on SUMOylation of coregula-
tors brought to the transcription complex by PRs, wt PR-B
(Figure 3A, C) or the PR-B K388R mutant (Figure 3B, D)
were co-expressed with increasing (20-1000 ng) concentra-
tions of SENP1, and tested on PRE2-Luc (Figure 3A, B) or
MMTV-Luc (Figure 3C, D). SENP1 enhanced PR-B-depen-
dent transcription in a dose-dependent manner on PRE2-
Luc, but was ineffective in modifying transcription by PR-B
K388R on the same reporter, indicating that the response
to SENP1 requires the PR SUMOylation site. This was con-
firmed on MMTV-Luc (or a single PRE, not shown) where
SENP1 had no effect despite strong transcription with wild-
type PR-B, confirming that the PREs of MMTV-LTR are
not PR SUMOylation sensitive (Figure 1). We conclude
that SENP1 modifies PR-dependent transcription directly
at the PR SUMOylation site, which is also required for the
cooperativity-driven synergy observed on a PRE2.
SENP action on PR: Mechanisms
Activation functions
To assess whether SENP modifies activity via AFs, two
PR deletion mutants were tested: 1) NT-B, a constitu-
tively active PR N-terminal construct [42] containing AF-
3, AF-1 and its ψKxE SUMOylation site, linked to the
DBD but missing the C-terminal AF-2 of the LBD
(Figure 4A); 2) DBD-LBD, the PR DBD linked to the C-
terminal LBD and its AF-2 (Figure 4B). The constructs
(100 ng DNA) were transfected into HeLa cells expres-
sing increasing concentrations (20-1000 ng) of DNA
encoding SENP1 or SENP1m and transcription was mea-
sured using PRE2- L u c .N T - Bi ss t r o n g l ya c t i v ei nt h e
absence of ligand (Figure 4A). Despite containing the PR
SUMOylation site, SENP1 was unable to further increase
this strong constitutive activity. This confirms that NT-B
is not SUMOylated in the absence of the LBD [33], mak-
ing it insensitive to SENP1. Rather, we observe a dose-
dependent repression by SENP1 requiring its catalytic
activity (compare SENP1 vs. SENP1m) suggesting an
effect by SENP1 on deSUMOylation of N-terminal inter-
acting coregulatory factors. Wild-type SENP1 does not
h a v ear e p r e s s i v ee f f e c to nt h e weak ligand-dependent
transcription of DBD-LBD (Figure 4B); likely the target of
different, possibly non-SUMOylated, C-terminal interact-
ing coregulators.
DNA binding specificity
Next we assessed the role of the PR DBD in mediating
effects of SENP1 using two additional constructs: 1) a
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Figure 2 SENP1 and SENP2 deSUMOylate PR-B and enhance their transcriptional activity. A) DeSUMOylation of PR-B by wt SENP1 and
SENP2. HeLa cells were cotransfected with pSG5-PR-B, GFP-SUMO-1 and SENP1 or SENP2 as indicated. Cells were grown in the presence (+) or
absence (-) of R5020. PR in cell extracts separated on SDS-PAGE, were detected with anti-PR 1294 monoclonal antibody. b-actin served as a
loading control. B) HeLa cells were transfected with the PRE2-Luc reporter plasmid in the presence of pSV40-Renilla as internal control along
with PR-B and increasing amounts (50-1000 ng) of SENP1, SENP1 mutant, or SENP2 expression vectors, or an empty vector control (-). Cells were
treated without (-) or with (+) 10 nM R5020 for 24 hrs before being assayed for luciferase activity. The relative luciferase activity of wt PR-B in the
presence of 10 nM R5020 is set as 100%.
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Page 5 of 18full-length PR-B Spec “specificity” mutant in which the
PR DBD was replaced by the DBD of ER (Figure 4C),
and 2) wild-type ER (Figure 4D). Both were tested on
tandem estrogen response elements (ERE2) linked to
luciferase. The PR-B specificity mutant was treated with
R5020 (since it contains a PR LBD); ER was treated with
17b-estradiol. The receptor-encoding constructs (100 ng
DNA) were transfected into HeLa cells without or with
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Figure 3 The enhancement of PR transcriptional activity by SENP1 depends on an intact SUMO conjugation site. HeLa cells were
transfected with the PRE2-Luc (A and B) or MMTV-Luc (C and D) reporter plasmids in the presence of pSV40-Renilla as internal control along with
PR-B (A and C) or PR-B K388R (B and D) expressing vectors, and a Flag-SENP1 expression vector at doses of 20, 50, 100, 200 and 1000 ng of DNA or
an empty vector control (-). Cells were treated without (-) or with (+) 10 nM R5020 for 24 hrs before being assayed for luciferase activity as in Figure
1. RLU of wt PR-B in the absence of hormone is set as 1. Statistical significance was computed by unpaired student’s t test. *p < 0.05.
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Page 6 of 18hormones together with increasing (20-1000 ng) SENP1
concentrations. The PR-B specificity mutant exhibited
weak ligand-dependent transcriptional activity, which
was dramatically enhanced by SENP1-mediated deSU-
MOylation in a dose-dependent manner. This suggests
that unlike the PR LBD, neither the PR DBD nor its
DNA binding site influence SUMOylation of the PR N-
terminus. The DBD dimer interface of steroid receptors
stabilizes binding to palindromic HREs. Interestingly,
disruption of the dimer interface markedly increases
transcriptional activity of receptors bound to multiple
PREs (Additional file 1: Figure S2) indicating that DBD
dimerization generally suppresses synergy. Wild-type
ERs were unaffected by SENP1, consistent with our
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Figure 4 The enhancement effect of SENP-1 on PR transcriptional activity requires full-length PR-B but not the PR DBD. HeLa cells were
transfected with the PRE2-Luc (A and B) or ERE2-Luc (C and D) reporter plasmids in the presence of pSV40-Renilla as internal control along with
NT-B (A), PR DBD-LBD (B), a PR-B specificity mutant containing the ER DBD (C) or wild-type ER (D) expression vectors, and SENP1 or SENP1m (A,
right panel) expression vectors at doses of 20, 50, 100, 200 and 1000 ng of DNA or an empty vector control (-). Cells were treated without (-) or
with (+) 10 nM R5020 (A and C) or 1 nM 17b-estradiol (E2) (D) for 24 hrs before being assayed for luciferase activity. The values are expressed as
relative luciferase units normalized to Renilla controls. Statistical significance was computed by unpaired student’s t test. *p < 0.05.
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SUMOylation. This failure is not controlled by the ER
DBD or EREs since both support SUMOylation in the
context of PR-B. Unlike N-terminal coregulatory pro-
teins of PR (Figure 4A), ER transcriptional coregulators
appear to be unaffected by their SUMOylation state.
Sensitivity to ligand
Since SUMOylation reduces PR-B sensitivity to hor-
mone [6,18] we speculated that deSUMOylation by
SENP would reverse this effect. To test this, HeLa cells
expressing constant levels of PR-B or the PRB K388R
mutant (50 ng DNA), in the absence or presence of con-
stant SENP1 levels (100 ng DNA) were treated 24 hrs
with R5020 at doses ranging from 10
-15 to 10
-8 M. Tran-
scription levels on PRE2-Luc were plotted as a percent
of maximal induction by 10
-8 M R5020 above “no hor-
mone” controls. Curve fitting was performed by Prism
Graph as described under “Experimental Procedures”
(Figure 5). SENP1 reduced the dose of R5020 required
for half-maximal transcription (EC50) by wild-type PR-B
~4.7-fold, from 2.74
-11 Mt o5 . 8 5
-12 M( F i g u r e5 A ) .
SENP1 had little or no effect on the EC50 (~1.5
-11 M)
of the SUMOylation deficient K388R mutant whose
intrinsic R5020-binding affinity exceeded that of wild-
type PR ~2-fold. This indicates that deSUMOylated PR
are exquisitely sensitive to very low hormone concentra-
tions; also explaining enhancement of the agonist prop-
erties of RU486 (Additional file 1: Figure S1C).
Saturating hormone concentrations were similar for the
two receptors (Figure 5B, D).
SENP, PR phosphorylation and MAPK signaling
PRs are phosphorylated on multiple serine residues
(Figure 1), three of which–S102, S294 and S345–are
currently known to be ligand-dependent [43-45]. Con-
tradictory reports indicate on the one hand that PR-B
phosphorylation is uncoupled from SUMOylation [6],
and on the other that MAPK-catalyzed S294 phosphory-
lation antagonizes PR-B SUMOylation [18]. To assess
interactions between deSUMOylation and MAPK signal-
ing, we analyzed transcription in the presence of SENP1
(100 ng) and MAP/ERK Kinase Kinase (MEKK1;
100 ng), a strong activator of MAPK-dependent PR
phosphorylation, using wild type PR-B, PR-B S294/345
phosphorylation-deficient mutants, or PR-B K388R
SUMOylation-deficient mutants (Figure 6). On wild-type
PR (Figure 6A), SENP1 and MEKK1 increased transcrip-
tion equally, and their combined effects were additive. A
k e yd i f f e r e n c eb e t w e e nt h et w oi st h a tS E N P 1d o e sn o t
alter basal transcriptional activity, but MEKK raises it
(Figure 6A, inset). The phosphorylation deficient mutant
(Figure 6B) remained responsive to SENP1, dissociating
S294/345 phosphorylation from deSUMOylation. Inter-
estingly, MEKK1 also activated this mutant suggesting
either that other PR sites, or PR coregulatory proteins,
are MEKK-regulated in the S294/345-deficient receptors.
Finally, SENP1 failed to hyperactivate the constitutively
active K388R mutant (Figure 6C), as would be expected.
However, MEKK1 was able to activate this SUMOyla-
tion-deficient PR or the constitutively active NT-B
(Additional file 1: Figure S3A), uncoupling MEKK-
dependent activation from PR K388 SUMOylation. Acti-
vation of MAPK signaling by overexpressing MEKK1
has complex, concentration-dependent effects on PR
SUMOylation. At low concentrations, MEKK1 induces
ligand-independent PR SUMOylation (Additional file 1:
Figure S3B, lanes 3). At high concentrations, MEKK1
suppresses hormone-dependent PR SUMOylation (Addi-
tional file 1: Figure S3B, lanes 6&8).
SENP, histone deacetylases (HDAC) and SRC-1 coactivation
Repression of the Elk-1 transcription factor by SUMOyla-
tion couples with recruitment to promoters of histone dea-
cetylases, to further repress Elk-1 target genes [46]. This
suggests that HDACs are involved in the transcriptional
repression by SUMO [46]. We asked whether HDACs are
involved in the synergy control and regulation of PR activ-
ity by SENP1. We first analyzed baseline effects of trichos-
tatin A (TSA)–an HDAC inhibitor that brings about
chromatin decondensation [47]–on PR-B-dependent tran-
scription of PRE2-Luc (Figure 7A). There was a marked
biphasic response. Compared to untreated controls, low
doses of TSA (50 and 100 nM) upregulated both basal and
liganded PR-B dependent transcription, while excessive
TSA doses (500 and 1000 nM) were strongly inhibitory.
Similar inhibitory effects of TSA have been attributed to
incompatibility between hyperacetylation of chromatin and
assembly of coactivators on the RNA pol II complex [48].
To assess this, we analyzed the ability of steroid receptor
coactivator 1 (SRC-1) to coactivate PR-B on PRE2-Luc,
at low (100 nM) or high (500 nM) TSA concentrations. At
low TSA concentrations (Figure 7B), HeLa cells express
sufficient endogenous SRC-1 to maximally coactivate PR-B
dependent transcription, and exogenous addition of excess
SRC-1 (20-1000 ng) does not alter these already high
levels. However, high TSA concentrations (Figure 7C)
repress transcription controlled by endogenous coactiva-
tors more than 90%, which exogenous SRC-1 (20-1000 ng)
is able to reverse. These data support the conclusion that
in HeLa cells, promoter hyperacetylation suppresses coac-
tivator recruitment to DNA-bound PR. Additionally, we
noted that high concentrations of TSA stabilize PR-B pro-
tein levels (Figure 8A; compare lane 1 vs. lanes 2-5), and
prevent ligand-dependent PR-B downregulation (compare
l a n e s6 ,7v s .8 - 1 0 ) .S u p p r e s s i o no fu n l i g a n d e da n d / o r
liganded PR protein turnover would also impede transcrip-
tion [49].
The relationship between HDAC inhibition and PR
deSUMOylation was therefore probed using low (100 nM)
TSA concentrations together with the deSUMOylase
Abdel-Hafiz and Horwitz BMC Molecular Biology 2012, 13:10
http://www.biomedcentral.com/1471-2199/13/10
Page 8 of 1810-16 10-14 10-12 10-10 10-8
-5
20
45
70
95
120
PR-B K388R
PR-B K388R+ SENP1
R5020 (M)
L
u
c
i
f
e
r
a
s
e
 
A
c
t
i
v
i
t
y
 
(
%
 
o
f
 
M
a
x
 
R
e
s
p
o
n
s
e
)
10-16 10-14 10-12 10-10 10-8 0
200
400
600
800
1000
PR-B K388R
PR-B K388R+ SENP1
R5020 (M)
R
L
U
A   B  
C   D  
10-16 10-14 10-12 10-10 10-8 -5
20
45
70
95
120
PR-B
PR-B + SENP1
R5020 (M)
L
u
c
i
f
e
r
a
s
e
 
A
c
t
i
v
i
t
y
 
(
%
 
o
f
 
M
a
x
 
R
e
s
p
o
n
s
e
)
10-16 10-14 10-12 10-10 10-8 0
100
200
300
400
500
600
PR-B
PR-B + SENP1
R5020 (M)
R
L
U
PRE2-Luc   PRE2-Luc  
PRE2-Luc   PRE2-Luc  

 


 



  


  

 
Figure 5 Overexpression of SENP1 raises PR-B sensitivity to hormone. HeLa cells were transfected with 50 ng of the PR-B (A) or PR-B K388R
(C) expression vectors, a PRE2-luc, and Renilla control plasmid in the presence or absence of 100 ng of SENP1 expression vector and treated
with ethanol or various concentrations of R5020 for 24 h. The average was plotted as a percentage of the maximal induction by 10 nM R5020
above no hormone levels. Curve fitting was performed by Prism Graph as described under “Experimental Procedures”. The S.D. of triplicate
values is indicated by the error bars. The corresponding relative luciferase activities were plotted for PR-B (B) and PR-B K388R (D). Statistical
significance was computed by unpaired student’s t test. *p < 0.05.
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Figure 6 The stimulatory effect of MEKK1 on PR-B transcriptional activity is independent of the SUMO conjugation site. HeLa cells were
transfected with 2 μg of PRE2-luciferase reporters together with 50 ng of wild type PR-B (A), PR-B S294/345 phosphorylation mutant (B), or PR-B
K388R SUMOylation deficient mutant (C) expression vectors and Renilla-Luc as an internal control in the presence or absence of 100 ng SENP1
and/or constitutively active MEKK1 expression vectors. The cells were treated for 24 hrs with the agonist R5020 (10 nM) then harvested and
lysed. The extracts were assayed for luciferase activities as in Figure 1.
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Figure 7 SRC-1 reverses the inhibitory effect of the HDAC inhibitor TSA on the PR transcriptional activity. A) HeLa cells were transfected
with 2 μg of PRE2-luciferase reporters together with 50 ng of a PR-B and Renilla-Luc as an internal control. The cells were treated for 24 hrs with
the agonist R5020 (10 nM), without (-) or with increasing amounts of trichostatin A (TSA). B&C ) HeLa cells were transfected with 2 μg of PRE2-
luciferase reporters together with 50 ng of a PR-B expression vector and Renilla-Luc as an internal control in the absence or the presence (+) of
increasing amount of SRC1. The cells were treated for 24 hrs with the agonist R5020 (10 nM), without (-) or with (+) 100 nM (B) or 500 nM (C)o f
TSA then harvested and lysed. The extracts were assayed for luciferase activities as in Figure 1. (*) Compared with control and (+) compared with
TSA treatment.
Abdel-Hafiz and Horwitz BMC Molecular Biology 2012, 13:10
http://www.biomedcentral.com/1471-2199/13/10
Page 11 of 18SENP1 
R5020  –   +  –  +  –   +  –   +     –   +  –  +   –  +  –   +   
–   –  +  +  –   –  +   +     –   –  +  +   –  –  +   +    TSA 
–   –  –  –  +   +  +   +     –   –  –  –   +  +  +   +   
PR-B PR-B  K388R 
0
1000
2000
3000
4000
R
L
U
PR-B/PRE2-Luc 
B  
PR-B 
TSA 
R5020 
E-actin 
A 
1    2    3    4    5   6   7    8   9  10 
EtOH 


 


 

 


  

 
Figure 8 HDACs are not a major target for SENP1 action on PR transcriptional activity. A) TSA enhances PR-B protein stability. HeLa cells
were transiently transfected with expression vectors encoding wild type PR-B. Cells were treated 24 hrs without (-) or with (+) 10 nM R5020 in
the presence of increasing concentration of TSA. Western blot analysis was performed on cell extracts probed with the anti-PR1294 monoclonal
and anti b-actin antibodies. B) HeLa cells were transfected with 2 μg of PRE2-luciferase reporters together with 50 ng of a PR-B (left), or the PR-B
K388R mutant (right) expression vectors and Renilla-Luc as an internal control in the presence or absence of 100 ng SENP1 expression vectors.
The cells were treated for 24 hrs with the agonist R5020 (10 nM), without (-) or with (+) 100 nM TSA then harvested and lysed. The extracts
were assayed for luciferase activities as in Figure 1. Statistical significance was computed by unpaired student’s t test. *p < 0.05.
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(Figure 8B, left) or the PRB K388R mutant (Figure 8B,
right) in the absence (-) or presence (+) of SENP1 (100 ng)
and/or TSA (100 nM). On wild-type PR-B, either TSA
alone or SENP1 alone caused the expected increase in
transcription. The two together were additive, suggesting a
lack of interaction between them. On the K388R SUMOy-
lation-deficient mutant, TSA was especially potent in
hyperactivating the already strong basal activity. SENP1, as
expected, had no effect on this basal activity. When com-
bined with TSA, SENP1 also had no effect, suggesting that
HDAC activity does not markedly contribute to transcrip-
tion synergy.
Discussion
SUMO-dependent transcriptional repression and synergy
Various regulators of SUMO-dependent transcriptional
repression have been proposed, which include chromatin-
associated proteins [50], histone deacetylases [46], the
SUMO-binding death-domain associated protein DAXX
[51], the DEAD-box protein DP-103 [52], and the nuclear
matrix protein NXP-2 [53]. The link between relief from
SUMOylation and transcriptional synergy on complex
promoters was first observed for GR [21,24,54,55] and
later expanded to other transcription factors including the
nuclear receptors AR, MR and PR [6,19,56], and transcrip-
tion factors like C/EBP, SF1, MITF and ZBP89 [22,57-60].
GRs are modified post-translationally at three consensus
SUMO conjugation sites, two in the N-terminus, one in
the LBD [24,54,55]. Mutation of both N-terminal sites
strongly enhances GR-dependent transcription on dual
hormone response elements (HREs), but not on the
MMTV-LTR [54]. These two N-terminal GR sites, dubbed
“synergy control motifs” [21], require an intact receptor
LBD and an engaged DBD dimerization interface. Holm-
storm et al. [54] propose that stable binding of SUMOy-
lated GR to multiple HREs allows recruitment of
inhibitory factors, but that on non-canonical half-site ele-
ments such as the MMTV-LTR, SUMOylated GR escape
these negative influences [54]. Consistent with these
observations, we observe that t h es i n g l eN - t e r m i n a lP R
SUMOylation motif controls transcriptional synergy on
multiple PREs but not at a single PRE [6] or the MMTV-
LTR (Figure 1).
Like GR, AR are SUMOylated at two N-terminal Lys
residues and mutation of one (K385) enhances coopera-
tivity on palindromic but not direct-repeat HREs. Calle-
vaert et al. [61] posit that this is a reflection of differing
AR dimer conformations on the two types of DNA bind-
ing sites. The DBD dimer interface of steroid receptors
stabilizes binding to palindromic HREs but this structure
forms only after the receptors have bound to DNA [62].
This interface is essential for transcriptional activity on a
single HRE, so that mutations in either MR or GR that
destabilize it, disrupt receptor/DNA interactions. How-
ever, paradoxically these same dimer interface mutations
markedly increase synergistic activity of receptors bound
to multiple HREs while only modestly increasing DNA
binding (62). Mutations in PRs that destabilize the DBD
dimer interface also disrupt receptor binding and activity
at a single PRE [11], while the same mutations dramati-
cally enhance PR transcriptional activity on promoters
containing multiple PREs (PR-B DX; Additional file 1:
Figure S2). These mutants are still subject to SUMOyla-
tion however (data not shown), suggesting that, as pre-
viously reported for GR [54], SUMOylation is upstream
of synergy control. Liu et al. (62) postulate that an inhibi-
tory interaction between the N-terminus and the wild-
type DBD dimer interface is relieved by DBD mutations,
thereby promoting cooperative binding among multi-
meric receptors and/or coregulatory factors. We specu-
late that this inhibitory factor is the 97aa SUMO peptide
bound at the N-terminus. Its removal, by mutation of the
SUMOylation motif or enzymatically with SENP1,
relieves the inhibition and permits assembly of higher
order PR complexes on DNA.
DeSUMOylation by SENP
The SENPs deconjugate SUMO-modified proteins and are
critical for maintaining physiological ratios of SUMOy-
l a t e dt od e S U M O y l a t e ds u b s t r a t e s .S t u d i e si nk n o c k o u t
mice demonstrate that a fine balance of SUMOylation/
deSUMOylation is required for normal embryonic devel-
opment [29]. This balance may be altered in malignancies.
Persistent elevation of SENP1 facilitates the transforma-
tion of the normal prostate to a dysplastic state in trans-
genic mice. Increased SENP expression is observed in
malignancies including oncocytic thyroid adenomas, colon
and prostate cancers [28,63-66]. Remarkably this control
by SUMOylation is maintained despite the fact that
usually, < 5% of target proteins are covalently modified
(Figure 2A, for example).
SENP1 stimulates the transcriptional activity of ARs and
two different mechanisms have been proposed. Cheng et al.
[20] suggest that the transactivating effects of SENP1 do
not involve SUMO deconjugation of the receptors, but
rather cleavage of SUMO from HDAC1 thereby alleviated
its repressive effect on AR activity. In contrast, Kaikkonen
et al. [19] demonstrate that effects of SENP1 and SENP2
require intact SUMO acceptor sites in AR, indicating that
the coactivating effects of the enzymes are directly on the
receptors. We show here that both SENP1 and SENP2 sti-
mulate the transcriptional activity of exogenous PR in HeLa
cells (Figure 2B), and endogenous PR in T47Dco cells
(Additional file 1: Figure S1B). This stimulatory effect is
dependent on their enzymatic activity (Figure 2B), requires
an intact PR SUMO conjugation site (Figure 3A, B), and
functions only at promoters containing multiple PREs
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indirectly, we used the HDAC inhibitor TSA. Inhibition of
HDAC activity by TSA did not prevent SENP1 stimulation
of wild-type PR (Figure 8B). SUMOylation-deficient PR
were similarly affected by TSA, indicating that other
mechanisms are responsible for the suppressive effects of
SUMOylation on PR activity. This is in agreement with a
recent report showing that wild type and SUMOylation
deficient AR are similarly influenced by TSA [19]. Taken
together we conclude that SENPs target the PR SUMOyla-
tion site synergy control function.
PR phosphorylation and SUMOylation
Both PR SUMOylation and PR phosphorylation are
enhanced with similar kinetics by progestin binding to
the receptors [18]. However, these two posttranslational
protein modification steps appear to be independent of
one another. We have shown that K388 SUMOylation
of PRs, previously mutated at their MAPK-targeted, pro-
gestin-dependent Ser294/344/345 phosphorylation sites,
is comparable to SUMOylation of wild-type PRs [6]. On
the other hand, activation of MAPK signaling by overex-
pressing MEKK1 has complex, concentration-dependent
effects on PR SUMOylation. At low concentrations,
MEKK1 induces ligand-independent PR SUMOylation
(Additional file 1: Figure S3B, lanes 3) and increases
basal PR-dependent transcription (Figure 6). At high
concentrations, MEKK1 suppresses hormone-dependent
PR SUMOylation (Additional file 1: Figure S3B, lanes
6&8). These contrasting dual activities of MEKK1 sug-
gest that the effects of MAPK on PR SUMOylation are
indirect, through alteration of the activity of the general
SUMOylation machinery. The molecular mechanisms by
which MAPK signaling could indirectly influence PR
SUMOylation include changes in the amounts and/or
the activities of E3 ligases and cleaving enzymes [67,68].
In concert with our conclusions, Kaikkonen et al. [19]
recently showed that AR phosphorylation has no effects
on AR SUMOylation. Indeed, there are no phosphoryla-
tion-dependent SUMOylation motifs in either AR or PR.
That PR phosphorylation at S294 does not affect PR
SUMOylation is consistent with our data showing that
there are no significant differences between the tran-
scriptional activities of wild-type PR and an S294A PR
mutant (Figure 6A, B). Qiu et al. [69] have shown simi-
larly robust transcription with a PR S294A mutant. In
contrast, Daniel et al. [18] concluded that an association
does exist between hormone-dependent PR phosphory-
lation and PR SUMOylation. The reasons for these dif-
ferences are unclear but may be related to experimental
conditions including use of DNA concentrations for
receptor expression at which squelching effects are
observed [6].
In contrast to the stimulatory effects of SENP1 on PR
activity (Figure 3A), the effect of MAPK signaling on PR
transcriptional activity is not related directly to the deSU-
MOylase effect seen at high concentration (Additional
file 1: Figure S3B). First, MEKK1 enhanced hormone
independent PR activity (Figure 6A inset and Shen et al.
[49]). Second, constitutively active NT-B cannot be
SUMOylated, but can still be activated by MEKK1 (Addi-
tional file 1: Figure S3A). Third, although SUMOylation
has no effect on the MMTV promoter (Figure 1C),
MEKK enhances PR dependent activity on this promoter
(data not shown). Taken together, our results suggest
that the effects of MEKK do not depend on modulation
of PR SUMOylation.
Acetylation and SUMOylation
Acetylation of steroid receptors results in either tran-
scriptional activation or repression, depending on altera-
tions in DNA binding affinities, coregulator recruitment,
or hormone responsiveness [16,70-72]. Acetylation and
SUMOylation can in theory compete for the same Lys
residue of some proteins [73]. In response to hormones,
PRs are acetylated at a Lys-rich KxKK motif (aa 638-
641) conserved in other steroid receptors, and located in
the C-terminal hinge region [16]. However, for PR, a
Lys to Arg mutation of these residues does not influence
N-terminal SUMOylation [16]. We show that SENP1
does not influence the transcriptional activity of DBD-
LBD (Figure 4B) which contains the acetylation motif
(Figure 1A), suggesting dissociation between hinge
region acetylation and deSUMOylation.
It has been suggested that SUMOylation represses tran-
scription by recruiting repressors, including HDAC to
SUMOylated substrates [46]. However, the transcriptional
activities of wild-type and SUMOylation-deficient mutant
PRs are both increased by the HDAC inhibitor TSA
(Figure 8B), suggesting that other mechanisms are respon-
sible for inhibition of PR activity by SUMOylation. Effects
of TSA depend on the concentration used and the cell
type analyzed [74,75]. Indeed, low concentrations (50 and
100 nM) of TSA enhance PR transcriptional activity
(Figure 7A) as previously reported [76]. They also promote
PR acetylation [16]. However, the effects of TSA on tran-
scription are not related to receptor acetylation since an
acetylation-deficient PR-B mutant retains heightened tran-
scriptional activity [16]. On the other hand, at high con-
centrations (500 and 1000 nM) TSA markedly inhibits PR
transcriptional activity (Figure 7A), and enhances protein
stability (Figure 8A, lanes 9, 10). These results are in
agreement with studies showing that TSA increases ER
acetylation as well as protein stability without affecting ER
transcript levels [71]. The inhibitory effect of high TSA
levels on PR activity may in part be due to failed ligand
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to inhibition of coactivator expression and/or assembly.
As we show in Figure 7C, overexpression of SRC1 relieves
TSA inhibition in a dose dependent manner.
Conclusions
PRs are major markers in breast cancer. Their presence
indicates that a tumor is hormone-dependent and a can-
didate for endocrine therapies. The role of progesterone
in activating these transcription factors is complex, how-
ever. After binding PR, progestin agonists and antago-
nists can have either transcriptional activating or
suppressive effects modulated in part by enhancing or
suppressing PR SUMOylation [6,18,31,33,35]. This study
defines the roles of the SUMO-specific SENP proteases
and SUMOylation on PR-dependent transcriptional
synergy. 1. We show that deSUMOylation by SENP1
enhances transcriptional synergism in a promoter-speci-
fic manner. 2. We also show that SENPs, through their
catalytic activity, act at the single K388 PR SUMOyla-
tion site, which if mutated eliminates transcriptional
synergism by SENPs. 3. The enzymes can act only on
hormone-bound full-length PRs and increase the ligand
sensitivity of the receptors. 4. SUMOylation effects on
PR transcriptional synergism are dissociable from recep-
tor phosphorylation, SRC-1 coactivation or recruitment
of HDACs to the promoter. We conclude that reversible
SUMOylation/deSUMOylation of a minor PR protein
subpopulation tightly controls the overall transcriptional
activity of the receptors at complex synthetic promoters.
Of note we previously showed a requirement for PR
SUMOylation to transrepress ER thereby altering tumor
responses to estrogens [33]. Taken together, our data
suggest that the PR SUMO modification pathway criti-
cally modifies the response of a tumor to estrogens, pro-
gestins and antiprogestins–hormones that are major
therapeutics for breast cancers.
Methods
Plasmids
The expression plasmids pSG5 hPR, encoding human
PR-B and HEGO, encoding human ER, cloned into
pSG5 were a gift of P. Chambon (Strasbourg, France).
C l o n i n go fp S G 5h P R 1K 3 8 8 R ,p S G 5h P R 1S 2 9 4 / 3 4 4 /
345A, pSG5 NT-B, pSG5 hPR1 R606A (PR-B DNA
dimerization mutant was a gift of B. Jacobsen), pCMV5-
MEKK1 and pSG5 DBD-LBD were described previously
[4,11,17,33]. Wild type pEGFP-SUMO-1 was a gift of J.
Palvimo and O. Janne (University of Helsinki, Helsinki,
Finland). pCR3.1-SRC-1e was a gift of B. O’Malley (Bay-
lor College of Medicine, Houston, TX). ERE2-Luc, PRE2-
Luc and MMTV-Luc reporter plasmids were described
previously [4]. Flag-SENP1, Flag-SENP1 mutant (R630L,
K631M) and Flag-SENP2 were gifts of E. Yeh (M. D.
Anderson, Houston, TX).
Transcription assays
HeLa cells were plated in minimum Eagle’s medium con-
taining 5% FBS (twice charcoal-stripped for experiments
with full-length PR or DBD-LBD) at a density of 1.2 ×
10
5 cells per 60 mm dish, 1 day prior to transfection.
Cells were transfected by calcium phosphate co-precipi-
tation [42] with concentrations of expression vectors
indicated in the figures. Reporter plasmids were added at
2 μg/dish. SV40-Renilla luciferase was added as an inter-
nal control at 20 ng/dish. Twenty four hours later, cells
expressing LBD-containing constructs were washed and
incubated 24 hrs with the synthetic progestin R5020
(Sigma Chemical Co., St. Louis, MO) at final concentra-
tions indicated in the figures. Control cells received etha-
nol only. Cells were collected in 150 μl lysis buffer
(Promega), and 50 μl were analyzed on a dual lumin-
ometer [42]. Results were normalized to Renilla luciferase
activity and expressed as indicated in the figures. Repli-
cate experiments were done in duplicate.
Immunoblotting
Whole cell extracts were prepared from HeLa cells tran-
siently transfected with PR expression vectors as
described [33]. Cells were treated with 10 nM R5020
and/or Trichostatin A (TSA). Lysates containing equal
protein concentrations were resolved by SDS-PAGE,
transferred to nitrocellulose, and probed with anti-PR
PgR1294 (DakoCytomation) or anti-b-actin AC-74
(Sigma) monoclonal antibodies. Bands were detected by
enhanced chemiluminescence (PerkinElmer Life
Sciences). For PR SUMOylation, HeLa cells cotrans-
fected with PR and GFP-tagged SUMO-1 were collected
in PBS containing 20 mM N-ethylmaleimide, and cell
extracts were prepared in 50 mM Tris-HCl (pH 7.8),
150 mM NaCl, 5 mM EDTA, 15 mM dithiothreitol, a
protease inhibitor mixture (Roche Molecular Biochem-
icals), and 20 mM N-ethylmaleimide. The expressed
proteins were resolved on SDS-PAGE, and conjugated
protein was detected by immunoblotting with PgR1294.
Statistical analysis
Prism GraphPad software version 4 (GraphPad Software
Inc. La Jolla, CA). was used to determine least-squares
best fit of the experimental data to the theoretical dose-
response curve. All values represent at least three inde-
pendent experiments and are expressed as the means ±
SD. Data sets were analyzed with GraphPad Prism 4
Statistical significance was determined by two-tailed
unpaired student’s t test, and the differences were con-
sidered statistically significant at a P value of 0.05.
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Additional file 1: Figure S1. A) DeSUMOylation of PR by SENP1
depends on its catalytic activity. HeLa cells were transiently transfected
with expression vectors encoding wild type PR-B together with a GFP-
SUMO-1 expression vector (+), and wild type or mutant (m) SENP1. Cells
were treated 24 hrs without (-) or with (+) 10 nM R5020. Western blot
analysis was performed on cell extracts probed with the anti-PR1294
monoclonal antibody or anti -actin control. B) SENP1 enhances PR-B
activity in T47D breast cancer cells. PR-negative T47D-Y breast cancer
cells stably expressing PR-B were transfected with the PRE2-Luc reporter
plasmid in the presence of pSV40-Renilla as internal control along with
increasing amount (20-1000 ng) of SENP1 expression vector, or an empty
vector control (-). Cells were treated without (-) or with (+) 10 nM R5020
for 24 hrs before being assayed for luciferase activity. C) SENP1
enhances transcription by the partial agonist RU486. HeLa cells were
transfected with 2 g of PRE2-luciferase reporters together with 50 ng of
a PR-B expression vector and Renilla-Luc as an internal control in the
presence or absence of 100 ng SENP1 or SENP1m expression vectors.
The cells were treated for 24 hrs with the agonist R5020 (10 nM), partial
agonist RU486 (100 nM), or the pure antagonist ZK98299 (100 nM) then
harvested and lysed. The extracts were assayed for luciferase activities as
in Figure 1. Figure S2. The PR DBD dimerization interface is
necessary for effective synergy control. HeLa cells were transfected
with 2 g of PRE2-luciferase reporters together with 50 ng of a wild type
PR -B, the PR-B K388R SUMOylation deficient, or a PR-B DBD dimerization
mutant (PR-B DX) expression vector and Renilla-Luc as an internal control
in the presence or absence of 100 ng SENP1 expression vectors. The
cells were treated for 24 hrs with the agonist R5020 (10 nM), then
harvested and lysed. The extracts were assayed for luciferase activities as
in Figure 1. Figure S3. A) The stimulatory effect of MEKK1 on PR-B
transcriptional activity is LBD and hormone independent. HeLa cells
were transfected with 2 g of PRE2-luciferase reporters together with 500
ng of NTB-DBD, a constitutively active PR N-terminal expression vector in
the presence of pSV40-Renilla as internal control along with increasing
amount (5-200 ng) of constitutively active MEKK1 expression vector, or
an empty vector control (-). The extracts were assayed for luciferase
activities as in Figure 1. B) Concentration dependent effect of MEKK1
on PR SUMOylation. HeLa cells were transiently transfected with
expression vectors encoding wild type PR-B together with a GFP-SUMO-1
expression vector (+) in the absence (-) or presence of increasing
amount of MEKK1 expression vector. Cells were treated 24 hrs without (-)
or with (+) 10 nM R5020. Western blot analysis was performed on cell
extracts probed with the anti-PR1294 monoclonal antibody or anti -actin
control.
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